Cargando…

Podocyte ACE2 protects against diabetic nephropathy

As new components of the renin–angiotensin system (RAS) are elucidated, our understanding of the complexities of their interactions also advances. Previous studies have determined that podocytes possess a local RAS that can generate angiotensin II. Podocytes have also been shown to express angiotens...

Descripción completa

Detalles Bibliográficos
Autor principal: Harris, Raymond C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Nephrology. Published by Elsevier Inc. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112297/
https://www.ncbi.nlm.nih.gov/pubmed/22791320
http://dx.doi.org/10.1038/ki.2012.127
_version_ 1783513452227067904
author Harris, Raymond C.
author_facet Harris, Raymond C.
author_sort Harris, Raymond C.
collection PubMed
description As new components of the renin–angiotensin system (RAS) are elucidated, our understanding of the complexities of their interactions also advances. Previous studies have determined that podocytes possess a local RAS that can generate angiotensin II. Podocytes have also been shown to express angiotensin-converting enzyme 2 (ACE2), which can decrease angiotensin II levels by generation of angiotensin-(1–7). Nadarajah et al. now show that increased podocyte ACE2 activity can attenuate the development of diabetic nephropathy.
format Online
Article
Text
id pubmed-7112297
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher International Society of Nephrology. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71122972020-04-02 Podocyte ACE2 protects against diabetic nephropathy Harris, Raymond C. Kidney Int Article As new components of the renin–angiotensin system (RAS) are elucidated, our understanding of the complexities of their interactions also advances. Previous studies have determined that podocytes possess a local RAS that can generate angiotensin II. Podocytes have also been shown to express angiotensin-converting enzyme 2 (ACE2), which can decrease angiotensin II levels by generation of angiotensin-(1–7). Nadarajah et al. now show that increased podocyte ACE2 activity can attenuate the development of diabetic nephropathy. International Society of Nephrology. Published by Elsevier Inc. 2012-08-01 2015-12-16 /pmc/articles/PMC7112297/ /pubmed/22791320 http://dx.doi.org/10.1038/ki.2012.127 Text en Copyright © 2012 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Harris, Raymond C.
Podocyte ACE2 protects against diabetic nephropathy
title Podocyte ACE2 protects against diabetic nephropathy
title_full Podocyte ACE2 protects against diabetic nephropathy
title_fullStr Podocyte ACE2 protects against diabetic nephropathy
title_full_unstemmed Podocyte ACE2 protects against diabetic nephropathy
title_short Podocyte ACE2 protects against diabetic nephropathy
title_sort podocyte ace2 protects against diabetic nephropathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112297/
https://www.ncbi.nlm.nih.gov/pubmed/22791320
http://dx.doi.org/10.1038/ki.2012.127
work_keys_str_mv AT harrisraymondc podocyteace2protectsagainstdiabeticnephropathy